Napolitano Janet 4
4 · Vir Biotechnology, Inc. · Filed May 28, 2026
Research Summary
AI-generated summary of this filing
Vir Biotechnology (VIR) Director Janet Napolitano Receives 24,000-Share Award
What Happened Janet Napolitano, a director of Vir Biotechnology, was granted equity awards on May 27, 2026: 8,000 restricted stock units (RSUs) and 16,000 derivative awards (stock-option type). Both grants show an acquisition price of $0.00 (no cash paid). The combined award totals 24,000 shares; the RSUs and the derivative awards vest in full on May 27, 2027.
Key Details
- Transaction date: 2026-05-27; reported on Form 4 filed 2026-05-28 (timely filing).
- Award amounts and prices: 8,000 RSUs @ $0.00; 16,000 derivative/option-type awards @ $0.00.
- Vesting: RSUs vest in full on May 27, 2027 (F2). The derivative awards vest and become exercisable in full on May 27, 2027 (F3).
- Shares owned after transaction: not disclosed in the filing.
- Transaction code: A = grant/award. No 10b5-1 plan, tax-withholding, or late filing flags noted.
Context These grants are compensation awards for a director rather than open-market purchases or sales. RSUs convert to shares upon vesting; the 16,000 derivative awards are stock-option–type awards that will be exercisable only after the stated vesting date. Awards are common for board service and do not by themselves indicate an immediate buying or selling signal.
Insider Transaction Report
- Award
Common Stock
[F1][F2]2026-05-27+8,000→ 24,416 total - Award
Stock Option (Right to Buy)
[F3]2026-05-27+16,000→ 16,000 totalExercise: $9.10From: 2027-05-27Exp: 2036-05-26→ Common Stock (16,000 underlying)
Footnotes (3)
- [F1]Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
- [F2]The RSUs will vest in full on May 27, 2027.
- [F3]The shares subject to the stock option will vest and become exercisable in full on May 27, 2027.